A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

Phase 2 Completed 89 enrolled Lumosa Therapeutics Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)

Timeline

Start: 2022-08-17
Primary completion: 2025-05-23
Completion: 2025-05-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LT3001	Unknown	—	Intravenous

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

Summary

Timeline

Drugs

Indications